KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Research & Development (2016 - 2025)

Biogen has reported Research & Development over the past 17 years, most recently at $509.4 million for Q4 2025.

  • Quarterly results put Research & Development at $509.4 million for Q4 2025, down 0.76% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (down 10.19% YoY), and the annual figure for FY2025 was $1.8 billion, down 10.19%.
  • Research & Development for Q4 2025 was $509.4 million at Biogen, up from $436.1 million in the prior quarter.
  • Over the last five years, Research & Development for BIIB hit a ceiling of $736.3 million in Q3 2023 and a floor of $75.0 million in Q4 2023.
  • Median Research & Development over the past 5 years was $522.4 million (2024), compared with a mean of $522.9 million.
  • Biggest five-year swings in Research & Development: skyrocketed 1600.73% in 2021 and later crashed 87.53% in 2023.
  • Biogen's Research & Development stood at $699.5 million in 2021, then decreased by 14.0% to $601.6 million in 2022, then crashed by 87.53% to $75.0 million in 2023, then soared by 584.4% to $513.3 million in 2024, then fell by 0.76% to $509.4 million in 2025.
  • The last three reported values for Research & Development were $509.4 million (Q4 2025), $436.1 million (Q3 2025), and $399.0 million (Q2 2025) per Business Quant data.